Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge?

• If you are wondering whether Ligand Pharmaceuticals at US$221.24 is still offering value after a big run, you are not alone. That is exactly what this article will unpack.
• The stock has returned 5.9% over the last 7 days, 18.4% over the last 30 days, 16.4% year to date, 104.7% over 1 year and 209.0% over 3 years, with a 5 year return of 106.6%.
• Recent headlines around Ligand Pharmaceuticals have focused on its role in the pharmaceuticals and biotech space and how the market is reassessing companies with specialized drug platforms. This provides useful context for these strong return figures. For investors, this news flow helps frame whether the current price reflects sentiment shifts or something more fundamental.
• On our valuation checks, Ligand Pharmaceuticals currently has a value score of 2 out of 6. Next we will look at what different valuation methods say about that score, then finish with a more holistic way to think about valuation beyond the usual metrics.

Ligand Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Ligand Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts those back to today’s dollars to estimate what the business might be worth now.

For Ligand Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $46.6 million, and analyst and extrapolated estimates have free cash flow reaching $206.8 million by 2030. Simply Wall St uses analyst inputs through 2028, then extends the series for later years, including the 2030 figure.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about $279.18 per share. With the current share price at roughly $221.24, the DCF implies the stock trades at a 20.8% discount to this estimate, which indicates that the shares screen as undervalued on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ligand Pharmaceuticals is undervalued by 20.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ligand Pharmaceuticals.

Approach 2: Ligand Pharmaceuticals Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. It links directly to what matters most over time, which is how much profit the business generates relative to its share price.

A higher or lower P/E often reflects what the market is baking in around future growth and risk. Stronger expected earnings growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty usually lines up with a lower, more conservative multiple.

Ligand Pharmaceuticals currently trades on a P/E of 35.45x. That is above both the Pharmaceuticals industry average of 17.99x and the peer group average of 32.01x. Simply Wall St also calculates a proprietary “Fair Ratio” for the stock of 17.31x. This Fair Ratio is designed to capture what a reasonable P/E might be after considering factors such as earnings growth, profit margins, the company’s industry and size, and key risks, which makes it more tailored than a simple comparison with peers or the broad industry.

Compared with this Fair Ratio, Ligand Pharmaceuticals current P/E of 35.45x screens as higher than what the model suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Ligand Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to think about valuation, and that is through Narratives. Simply Wall St offers this on the Community page so you can write a clear story for Ligand Pharmaceuticals that ties your assumptions about future revenue, earnings and margins into a financial forecast. You can then compare your own Fair Value to the current price to decide whether it looks attractive or expensive, and see that view update automatically when new news or earnings arrive. For example, one investor might build a bullish Ligand Pharmaceuticals Narrative around the US$244.56 Fair Value, expanding royalty portfolio, 9.29% revenue growth rate, 38.87% profit margin and 48.42x future P/E. Another investor might focus on risks like drug pricing pressure, concentration in a few royalty assets and the analyst price target range of US$155 to US$206 to arrive at a lower Fair Value. Both of those stories sit side by side on the platform so you can judge which one fits your own expectations best.

Do you think there’s more to the story for Ligand Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com